Micheal Bunger
Acute Care · Columbia, SCNPI 1881933885
Payments from drug & device makers
Across 715 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novartis$2K
- Amgen$2K
- Medtronic$1K
- AstraZeneca$996
- E.r. Squibb & Sons, L.L.C.$726
- plus $7K from 29 others
What the payments were for
- Food & beverage$15,451100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 47 | $2,125 |
| Novartis | 99 | $1,731 |
| Amgen | 87 | $1,513 |
| Medtronic | 62 | $1,484 |
| AstraZeneca | 58 | $996 |
| E.r. Squibb & Sons, L.L.C. | 48 | $726 |
| Edwards Lifesciences | 15 | $587 |
| Philips North America LLC | 22 | $567 |
| Merck | 31 | $537 |
| Pfizer | 27 | $537 |
| Johnson & Johnson | 32 | $507 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $498 |
| Alnylam Pharmaceuticals Inc. | 21 | $485 |
| Esperion Therapeutics, Inc. | 24 | $442 |
| Boehringer Ingelheim | 21 | $403 |
| Heartflow, Inc. | 5 | $292 |
| Scpharmaceuticals Inc. | 15 | $291 |
| Bayer | 15 | $228 |
| Novo Nordisk | 8 | $208 |
| Lexicon Pharmaceuticals, Inc. | 8 | $154 |
| Cvrx, Inc. | 4 | $152 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $150 |
| Atricure, Inc. | 5 | $142 |
| Abbott | 6 | $136 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $123 |
| Actelion Pharmaceuticals US, Inc. | 5 | $102 |
| Arbor Pharmaceuticals, Inc. | 5 | $73 |
| Bridgebio Pharma, Inc. | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Sanofi | 2 | $42 |
| Abiomed | 2 | $40 |
| Chiesi USA, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$650
- WATCHMAN Access System$625
- SAPIEN 3 Ultra RESILIA$316
- AZURE XT DR MRI SURESCAN$263
- Micra$222
- COBALT DR MRI SURESCAN$155
- Cobalt$128
- FFRct$114
- Barostim Neo System$104
- Repatha$104
How this compares
$15,465 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 257 | $264,344 |
| EntrestoSacubitril/Valsartan | 84 | $85,976 |
| XareltoRivaroxaban | 47 | $61,442 |
| Repatha SureclickEvolocumab | 53 | $42,515 |
| JardianceEmpagliflozin | 40 | $40,364 |
| BrilintaTicagrelor | 33 | $26,767 |
| FarxigaDapagliflozin Propanediol | 22 | $21,372 |
| Ranolazine ErRanolazine | 76 | $10,557 |
| NexletolBempedoic Acid | 11 | $7,408 |
| Metoprolol Succinate | 296 | $4,695 |
| Rosuvastatin Calcium | 134 | $3,932 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 73 | $3,020 |
| Atorvastatin Calcium | 205 | $2,649 |
| Carvedilol | 271 | $2,300 |
| ClopidogrelClopidogrel Bisulfate | 145 | $1,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $537 | $264,344257 claims |
| NovartisEntresto | $1,731 | $85,97684 claims |
| Johnson & JohnsonXarelto | $507 | $61,44247 claims |
| AstraZenecaBrilinta, Farxiga | $996 | $48,14055 claims |
| Boehringer IngelheimJardiance | $403 | $40,36440 claims |
| Esperion Therapeutics, Inc.Nexletol | $442 | $7,40811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in Columbia
- Michael GajewskiColumbia$62K
- Robin TrauflerColumbia$12K
- Linda VanduysColumbia$7K
- Aziz PetiwalaColumbia$7K
- Christina AdkinsColumbia$6K
- Brandon PalmerColumbia$6K
- Sarah Ford-SightlerColumbia$6K
- Jessica WheelerColumbia$6K
- Stacy SandersColumbia$6K
- Jazmine PorterfieldColumbia$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.